Can intensive lipid-lowering therapy improve the carotid Intima-media thickness in Japanese subjects under primary prevention for cardiovascular disease?

The JART and JART extension subanalysis

Hiroyuki Daida, Ryuji Nohara, Mitsumasa Hata, Kohei Kaku, Ryuzo Kawamori, Junji Kishimoto, Masahiko Kurabayashi, Izuru Masuda, Ichiro Sakuma, Tsutomu Yamazaki, Hiroyoshi Yokoi, Masayuki Yoshida

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Aim: This subanalysis aimed to clarify whether intensive lipid-lowering therapy with statins slows the progression of atherosclerosis in Japanese subjects under treatment for primary prevention of cardiovascular disease. Methods: This was a subanalysis of the Justification for Atherosclerosis Regression Treatment (JART) Study. We compared the efficacy of intensive lipid-lowering therapy and conventional therapy with respect to changes in the mean intima-media thickness (IMT) and serum lipid levels. We also evaluated changes in the mean IMT over 24 months of treatment and assessed the relationship between these changes and reductions in the LDL-C levels using a post-hoc analysis. Results: Intensive lipid-lowering therapy with rosuvastatin was associated with significantly smaller changes in the mean IMT and a greater reduction in the serum lipid levels in comparison to conventional therapy with pravastatin. The average net change in the mean IMT was 0.010 mm (n= 121) at 12 months and -0.004 mm (n= 56) at 24 months. A decrease in LDL-C was found to be associated with a smaller change in the mean IMT (p=0.0009; Jonckheere-Terpstra trend test). A greater reduction in serum LDL-C was found to be associated with a smaller change in the mean IMT. Similar associations were observed for the serum TC and non-HDL-C levels and LDL-C/HDL-C ratio. There were no notable differences in the incidence of serious adverse events among the LDL-C quartiles. Conclusions: Lowering the LDL-C level with intensive lipid-lowering therapy is associated with reduced changes in the IMT among Japanese subjects at moderate to high risk under treatment for primary prevention. Subjects suitable for primary prevention may receive cardiovascular benefits from intensive lipid-lowering therapy, in association with significantly slower IMT progression than that observed with conventional therapy.

Original languageEnglish
Pages (from-to)739-754
Number of pages16
JournalJournal of atherosclerosis and thrombosis
Volume21
Issue number7
DOIs
Publication statusPublished - Jan 1 2014

Fingerprint

Carotid Intima-Media Thickness
Primary Prevention
Atherosclerosis
Cardiovascular Diseases
Lipids
Therapeutics
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Pravastatin
Serum
Association reactions
oxidized low density lipoprotein

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine
  • Biochemistry, medical

Cite this

Can intensive lipid-lowering therapy improve the carotid Intima-media thickness in Japanese subjects under primary prevention for cardiovascular disease? The JART and JART extension subanalysis. / Daida, Hiroyuki; Nohara, Ryuji; Hata, Mitsumasa; Kaku, Kohei; Kawamori, Ryuzo; Kishimoto, Junji; Kurabayashi, Masahiko; Masuda, Izuru; Sakuma, Ichiro; Yamazaki, Tsutomu; Yokoi, Hiroyoshi; Yoshida, Masayuki.

In: Journal of atherosclerosis and thrombosis, Vol. 21, No. 7, 01.01.2014, p. 739-754.

Research output: Contribution to journalArticle

Daida, Hiroyuki ; Nohara, Ryuji ; Hata, Mitsumasa ; Kaku, Kohei ; Kawamori, Ryuzo ; Kishimoto, Junji ; Kurabayashi, Masahiko ; Masuda, Izuru ; Sakuma, Ichiro ; Yamazaki, Tsutomu ; Yokoi, Hiroyoshi ; Yoshida, Masayuki. / Can intensive lipid-lowering therapy improve the carotid Intima-media thickness in Japanese subjects under primary prevention for cardiovascular disease? The JART and JART extension subanalysis. In: Journal of atherosclerosis and thrombosis. 2014 ; Vol. 21, No. 7. pp. 739-754.
@article{be02331d30034434924544ade0b2c62f,
title = "Can intensive lipid-lowering therapy improve the carotid Intima-media thickness in Japanese subjects under primary prevention for cardiovascular disease?: The JART and JART extension subanalysis",
abstract = "Aim: This subanalysis aimed to clarify whether intensive lipid-lowering therapy with statins slows the progression of atherosclerosis in Japanese subjects under treatment for primary prevention of cardiovascular disease. Methods: This was a subanalysis of the Justification for Atherosclerosis Regression Treatment (JART) Study. We compared the efficacy of intensive lipid-lowering therapy and conventional therapy with respect to changes in the mean intima-media thickness (IMT) and serum lipid levels. We also evaluated changes in the mean IMT over 24 months of treatment and assessed the relationship between these changes and reductions in the LDL-C levels using a post-hoc analysis. Results: Intensive lipid-lowering therapy with rosuvastatin was associated with significantly smaller changes in the mean IMT and a greater reduction in the serum lipid levels in comparison to conventional therapy with pravastatin. The average net change in the mean IMT was 0.010 mm (n= 121) at 12 months and -0.004 mm (n= 56) at 24 months. A decrease in LDL-C was found to be associated with a smaller change in the mean IMT (p=0.0009; Jonckheere-Terpstra trend test). A greater reduction in serum LDL-C was found to be associated with a smaller change in the mean IMT. Similar associations were observed for the serum TC and non-HDL-C levels and LDL-C/HDL-C ratio. There were no notable differences in the incidence of serious adverse events among the LDL-C quartiles. Conclusions: Lowering the LDL-C level with intensive lipid-lowering therapy is associated with reduced changes in the IMT among Japanese subjects at moderate to high risk under treatment for primary prevention. Subjects suitable for primary prevention may receive cardiovascular benefits from intensive lipid-lowering therapy, in association with significantly slower IMT progression than that observed with conventional therapy.",
author = "Hiroyuki Daida and Ryuji Nohara and Mitsumasa Hata and Kohei Kaku and Ryuzo Kawamori and Junji Kishimoto and Masahiko Kurabayashi and Izuru Masuda and Ichiro Sakuma and Tsutomu Yamazaki and Hiroyoshi Yokoi and Masayuki Yoshida",
year = "2014",
month = "1",
day = "1",
doi = "10.5551/jat.19109",
language = "English",
volume = "21",
pages = "739--754",
journal = "Journal of Atherosclerosis and Thrombosis",
issn = "1340-3478",
publisher = "Japan Atherosclerosis Society",
number = "7",

}

TY - JOUR

T1 - Can intensive lipid-lowering therapy improve the carotid Intima-media thickness in Japanese subjects under primary prevention for cardiovascular disease?

T2 - The JART and JART extension subanalysis

AU - Daida, Hiroyuki

AU - Nohara, Ryuji

AU - Hata, Mitsumasa

AU - Kaku, Kohei

AU - Kawamori, Ryuzo

AU - Kishimoto, Junji

AU - Kurabayashi, Masahiko

AU - Masuda, Izuru

AU - Sakuma, Ichiro

AU - Yamazaki, Tsutomu

AU - Yokoi, Hiroyoshi

AU - Yoshida, Masayuki

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Aim: This subanalysis aimed to clarify whether intensive lipid-lowering therapy with statins slows the progression of atherosclerosis in Japanese subjects under treatment for primary prevention of cardiovascular disease. Methods: This was a subanalysis of the Justification for Atherosclerosis Regression Treatment (JART) Study. We compared the efficacy of intensive lipid-lowering therapy and conventional therapy with respect to changes in the mean intima-media thickness (IMT) and serum lipid levels. We also evaluated changes in the mean IMT over 24 months of treatment and assessed the relationship between these changes and reductions in the LDL-C levels using a post-hoc analysis. Results: Intensive lipid-lowering therapy with rosuvastatin was associated with significantly smaller changes in the mean IMT and a greater reduction in the serum lipid levels in comparison to conventional therapy with pravastatin. The average net change in the mean IMT was 0.010 mm (n= 121) at 12 months and -0.004 mm (n= 56) at 24 months. A decrease in LDL-C was found to be associated with a smaller change in the mean IMT (p=0.0009; Jonckheere-Terpstra trend test). A greater reduction in serum LDL-C was found to be associated with a smaller change in the mean IMT. Similar associations were observed for the serum TC and non-HDL-C levels and LDL-C/HDL-C ratio. There were no notable differences in the incidence of serious adverse events among the LDL-C quartiles. Conclusions: Lowering the LDL-C level with intensive lipid-lowering therapy is associated with reduced changes in the IMT among Japanese subjects at moderate to high risk under treatment for primary prevention. Subjects suitable for primary prevention may receive cardiovascular benefits from intensive lipid-lowering therapy, in association with significantly slower IMT progression than that observed with conventional therapy.

AB - Aim: This subanalysis aimed to clarify whether intensive lipid-lowering therapy with statins slows the progression of atherosclerosis in Japanese subjects under treatment for primary prevention of cardiovascular disease. Methods: This was a subanalysis of the Justification for Atherosclerosis Regression Treatment (JART) Study. We compared the efficacy of intensive lipid-lowering therapy and conventional therapy with respect to changes in the mean intima-media thickness (IMT) and serum lipid levels. We also evaluated changes in the mean IMT over 24 months of treatment and assessed the relationship between these changes and reductions in the LDL-C levels using a post-hoc analysis. Results: Intensive lipid-lowering therapy with rosuvastatin was associated with significantly smaller changes in the mean IMT and a greater reduction in the serum lipid levels in comparison to conventional therapy with pravastatin. The average net change in the mean IMT was 0.010 mm (n= 121) at 12 months and -0.004 mm (n= 56) at 24 months. A decrease in LDL-C was found to be associated with a smaller change in the mean IMT (p=0.0009; Jonckheere-Terpstra trend test). A greater reduction in serum LDL-C was found to be associated with a smaller change in the mean IMT. Similar associations were observed for the serum TC and non-HDL-C levels and LDL-C/HDL-C ratio. There were no notable differences in the incidence of serious adverse events among the LDL-C quartiles. Conclusions: Lowering the LDL-C level with intensive lipid-lowering therapy is associated with reduced changes in the IMT among Japanese subjects at moderate to high risk under treatment for primary prevention. Subjects suitable for primary prevention may receive cardiovascular benefits from intensive lipid-lowering therapy, in association with significantly slower IMT progression than that observed with conventional therapy.

UR - http://www.scopus.com/inward/record.url?scp=84905160163&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905160163&partnerID=8YFLogxK

U2 - 10.5551/jat.19109

DO - 10.5551/jat.19109

M3 - Article

VL - 21

SP - 739

EP - 754

JO - Journal of Atherosclerosis and Thrombosis

JF - Journal of Atherosclerosis and Thrombosis

SN - 1340-3478

IS - 7

ER -